acurxpharma.com (ACXP) - מקדם חוב לטווח ארוך להון

Acurx Pharmaceuticals (ACXP) brings together top infection experts to develop innovative antibiotics, supporting its staff with generous bonuses and insurance. Seamless raw material supplies eliminate disruptions in trials. The price action (separate_debt_long_eq) is recorded at 0.00. The business relies on the development of treatments against superbugs, which will ensure a steady income from patent utilization in major clinics.

For Acurx Pharmaceuticals (ACXP), the long-term debt-to-equity ratio reflects the balance between borrowed financing and equity. This metric compares liabilities with a maturity of more than one year against the amount of shareholders' equity. This ratio determines the company's degree of dependence on external creditors when implementing R&D projects to create antibiotics. The indicator's trend demonstrates the efficiency of debt load management. Low values confirm financial autonomy and the stability of the capital structure.